Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

escalating doses of TB-402. It is anticipated that the study will conclude by the end of 2010.

Patrik De Haes, CEO of ThromboGenics, commented on today's news "We are very excited about the start of the Phase II trial for TB-402. Our work to date suggests that this novel agent could represent a major advance in anti-coagulant therapy, given our expectation that it will cause fewer unwanted bleeding events and will require no monitoring of patients. This combined with its ability to be used as a "one-off" treatment could make TB-402 the anti-coagulant of choice to prevent DVT in patients undergoing surgery. Given the size of the market opportunity for TB-402 and the sales reach that will be needed to engage with the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent."

Svein Mathisen, CEO of BioInvent, also commented, "The initiation of this Phase II trial is another successful step forward in the clinical development of our antibody product development portfolio. TB-402 addresses a broad market and has potentially significant advantages over existing anti-coagulants. We are hopeful it will have application in a number of clinical settings."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.(1)

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.(2) Patients undergoing hip replacement or knee surgery are p
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  On May 9, ... ), the global business advisory firm dedicated to ... (the "Company"), announced that it has combined the ... formerly included within the Corporate Finance/Restructuring segment with ... to form a single integrated practice whose financial ...
(Date:5/21/2013)... 2013  The Lindsley F. Kimball Research Institute of the ... Grand Challenges Explorations winner, an initiative funded by ... Sara Lustigman , Head of the Laboratory of ... research project, titled Innovative 3-D in vitro ... to screen drugs to help eliminate onchocerciasis (river blindness) in ...
(Date:5/21/2013)... 21, 2013 Custom Learning Designs, ... eLearning solution using Tin Can API combined with ... CLD is a leading developer of training content ... companies worldwide. , Tin Can API is ... learners and trainers more accurately measure the Return ...
(Date:5/21/2013)... WA (PRWEB) May 21, 2013 Through ... trainings, and funds for lab equipment, 25 organizations will ... and importance of optics and photonics in daily life ... . , The organizations, located in 10 countries, are ... to be awarded by SPIE, the international society ...
Breaking Biology Technology:FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... Bone Care International, a Middleton-based University of Wisconsin spin-off, ... on "stabilized hydroxyvitamin D" that will extend protection of ... expire in 2021, covers the company's hormone therapy treatment ... as the new version of Hectorol which Bone Care ...
... Wis. - Health-care professionals received advice about integrating ... held June 8-9 at the Fluno Center in Madison. ... in clinical settings and the strategies for installation, as ... ,"I think it's critical to focus on the fact ...
... Fiserv, Inc. , has acquired Interactive Technologies, Inc., ... for large and mid-sized financial services organizations, for ... Summit, New Jersy, develops software for large international ... and other high-end providers of financial services to ...
Cached Biology Technology:Digitizing hospitals with the right tools 2Digitizing hospitals with the right tools 3Digitizing hospitals with the right tools 4
(Date:5/19/2013)... electricity-producing bacteria that can grow using hydrogen gas as ... sole source of carbon. Researchers at the University ... General Meeting of the American Society for Microbiology. , ... on hydrogen," says Amit Kumar, a researcher on the ... the Lovley Lab Group at the university. , Under ...
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) explores ... and lifestyle. , Individuals suffering from Crohn,s ... fatigue and poor quality of life. These symptoms ... A randomized, double blind, placebo-controlled study found for ... to significant relief of these symptoms. , ...
(Date:5/17/2013)... State University of New Jersey, and City University of ... Visikol TM that effectively clears organisms to be ... of chloral hydrate, which is one of the few ... regulated by the Drug Enforcement Administration (DEA) due to ... clearing agents, are vital for viewing organisms under a ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... ST. LOUIS , April 27 SAFC®, ... today announced a $6.25 million investment program to ... global ,Center of Excellence, for the seamless upstream and downstream ... of SAFC,s worldwide facilities initiative, is designed to better serve ...
... , PHILADELPHIA , April 27 Negotiations broke off early Tuesday ... Nurses & Allied Professionals (PASNAP) following a 14-hour session.  Talks are expected to resume ... , , Continued ... , , ...
... Holdings, Inc. (NYSE: MDC ) today announced that its board of directors has ... share on the Company,s common stock.  The dividend will be paid on Wednesday, May ... , , ... , , ...
Cached Biology News:SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 2SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 3SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 4SAFC(R) Announces $6.25 Million Expansion at Lenexa 'Center of Excellence' 5M.D.C. Holdings Declares Quarterly Cash Dividend 2
Mouse monoclonal [TONI-1] to Angiotensin II Type 1 Receptor (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 185 SwissProtID: P30556...
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
HSV-1 gE Envelope Protein (9H3)...
... Stem cells are functionally defined by ... ability to differentiate into multiple specialized progenitor ... along specific lineages. Neural stem cells (NSCs) ... types including astrocytes, neurons and oligodendrocytes. During ...
Biology Products: